
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is projected to experience growth in earnings per diluted share, with estimates increasing to $4.73 for 2025 and $5.17 for 2026, reflecting positive momentum driven by the strength of its Human Nutrition and Health segment. The company's recent financial performance showcased a top-line revenue of $255.5 million for 2Q25, which exceeded expectations and demonstrated a modest increase from both the prior quarter and the previous year. Additionally, with expectations of improving gross and net margins and a potential path to being debt-free by the end of next year, Balchem's robust balance sheet positions the company favorably for future growth and possible accretive M&A opportunities.
Bears say
Balchem Corporation's stock outlook is negatively impacted by several financial challenges, primarily reflected in its declining P/E multiple, which has decreased to 37.9x from 39.6x amid overall weakening of the share prices and earnings multiples in the comparables universe. Moreover, the company has reported sales in its animal health and nutrition segment of $56.4 million, which fell short of the estimated $60 million, alongside its industrial products segment realizing only $1.4 million in revenue against a projected $1.6 million. Contributing to this negative sentiment are risks related to slower-than-anticipated growth in core businesses, inflationary pressures, and the potential failure of its partner to secure FDA approval for a critical autism drug, as well as disruptions to operations in Europe due to regional conflicts.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares